Journal of Clinical Densitometry
Volume 9, Issue 1 , Pages 58-65 , January 2006

Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis

  • David W. Dempster

      Affiliations

    • Department of Pathology, Columbia University, New York, NY and Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY
    • Corresponding Author InformationAddress correspondence to David W. Dempster, PhD, Director, Regional Bone Center, Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993.
    • ,
  • Michael A. Bolognese

      Affiliations

    • Bethesda Health Research, Bethesda, MD

Received 26 July 2005 ,Revised 23 September 2005 ,Accepted 23 September 2005.

References 

  1. Siris ES, Rosen CJ, Harris ST, Abbott TA III, Barr CE, Silverman SL. 2005 Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Proc 6th International Symposium on Osteoporosis: Current Status and Future Directions, the National Osteoporosis Foundation, Washington, DC, 2005.
  2. US Department of Health and Human Services. 2004 Bone health and osteoporosis: a report of the Surgeon General (2004). Available at: http://www.hhs.gov/surgeongeneral/library/bonehealth/content.html. Accessed April 6, 2005.
  3. Body JJ. Management of primary osteoporosis. Acta Clin Belg. 2002;57:277–283
  4. National Osteoporosis Foundation. 2004 Osteoporosis fast facts. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed February 7, 2005.
  5. Melton LJ. How many women have osteoporosis now?. J Bone Miner Res. 1995;10:175–177
  6. Cooper C. 1996 Epidemiology and Definition of Osteoporosis. In: Osteoporosis: New Perspectives on Causes, Prevention, and Treatment. Compston JE, ed. Royal College of Physicians, London, 1–10.
  7. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. 1998 Osteoporos Int 8(Suppl 4):S7–S80.
  8. Kessel B. Hip fracture prevention in postmenopausal women. Obstet Gynecol Surv. 2004;59:446–455
  9. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR for the Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med. 1999;159:1215–1220
  10. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med. 1995;98(Suppl 2A):3S–8S
  11. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebal fractures. Lancet. 1996;348:1535–1541
  12. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax® International Trial Study Group. Osteoporos Int. 1999;9:461–468
  13. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83–91
  14. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352
  15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  16. Hulley S, Grady D, Bush T, et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  17. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49–57
  18. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856–861
  19. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287
  20. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–1008
  21. Harris ST, Siris E, Abbott TA, Barr CE, Rosen CJ. 2005 Reduced osteoporotic fracture risk in patients adherent to bisphosphonate therapy. Proc ENDO 2005 Annual Meeting, San Diego, CA, 2005.
  22. Gupta AK, Dlova N, Taborda P, et al. Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol. 2000;142:965–968
  23. Miner CM, Brown EB, Gonzales JS, Munir R. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry. 2002;63:232–240
  24. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005;20:121–130
  25. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception. 2004;69:189–195
  26. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315–1322
  27. Biskobing DM. Novel therapies for osteoporosis. Expert Opin Investig Drugs. 2003;12:611–621
  28. Papapoulos SE. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int J Clin Pract. 2003;57:417–422
  29. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol. 2001;28:49–53
  30. Negri AJ. Short-term compliance with alendronate 70 mg in patients with osteoporosis: the ECMO trial. Bone. 2003;25(5 Suppl):S209
  31. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24:1871–1886
  32. Hodsman A, Adachi J, Olszynski W. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis. CMAJ. 1996;155:945–948
  33. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97–106
  34. Bell NH, Johnson RH. Bisphosphonates in the treatment of osteoporosis. Endocrine. 1997;6:203–206
  35. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9:2643–2658
  36. Frith JC, Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res. 2003;18:204–212
  37. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235–242
  38. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 1991;6:1003–1011
  39. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004;15:423–433
  40. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther. 2003;25:19–34
  41. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin. 2005;21:391–401
  42. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792–798
  43. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249
  44. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004;44:951–965
  45. Boniva®(ibandronate sodium) tablets. [package insert] Nutley, NJ: Roche Laboratories Inc.; 2005;
  46. Bauss F, Wagner M, Hothorn LH. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol. 2002;29:990–998
  47. Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002;29:2200–2208
  48. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int. 1998;8:97–103
  49. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003;191:159–167
  50. Monier-Faugere MC, Geng Z, Paschalis EP, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res. 1999;14:1768–1778
  51. Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone. 2003;32:45–55
  52. Muller R, Hannan M, Smith SY, Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res. 2004;19:1787–1796
  53. Bauss F, Schenk RK, Hort S, Muller-Beckmann B, Sponer G. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods. 2004;50:25–34
  54. Tanko LB, Mouritzen U, Lehmann HJ, et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone. 2003;32:687–693
  55. Sartori L, Adami S, Filipponi P, Crepaldi G. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res. 2003;15:271–283
  56. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004;34:881–889
  57. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997;103:298–307
  58. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis. 2003;62:969–975
  59. Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004;34:890–899
  60. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res. 2001;16:1871–1878
  61. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88:4609–4615
  62. Tanko LB, Felsenberg D, Czerwinski E, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med. 2003;254:159–167

PII: S1094-6950(06)00018-7

doi: 10.1016/j.jocd.2005.09.004

Journal of Clinical Densitometry
Volume 9, Issue 1 , Pages 58-65 , January 2006

Article Tools

* Image Usage & Resolution